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Background: Inducible co-stimulator (ICOS) deficiency was the first monogenic defect 
reported to cause common variable immunodeficiency (CVID)-like disease in 2003. Since 
then, 16 patients have been reported worldwide with an increasing range of clinical 
phenotypes.
Objective: We sought to compare the clinical and immunological phenotype and pro-
vide clinical follow-up and therapeutic approaches for treating ICOS-deficient patients.
Methods: We describe the clinical and laboratory data of 15 patients with available 
clinical data. Previous publications and clinical assessment were used as data sources.
results: The observed ICOS gene mutations were all deletions leading to undetectable 
protein expression. The clinical phenotype of ICOS deficiency is much broader than ini-
tially anticipated and includes not only CVID-like disease but an increased susceptibility 
to viral and opportunistic infections, as well as cancer. Impaired B-cell development led 
to decreased memory B-cells in all patients, and hypogammaglobulinemia in all but one 
patient. Circulating CXCR5+ CD4+ follicular T-helper-cell numbers were also reduced in all 
patients. Treatment included immunoglobulin replacement, regular antibiotic prophylaxis, 
corticosteroids, and steroid-sparing agents. Three patients underwent hematopoietic 
stem cell transplantation; one of them died due to capillary leak syndrome on day 5 
posttransplantation.
conclusion: The disease spectrum of ICOS deficiency is expanding from solely B-cell 
to combined B- and T-cell immunodeficiency, suggesting genetic and environmental 
modifiers. Genetic diagnosis is the only tool to distinguish ICOS deficiency from other 
immunological defects. Patients with antibody deficiency, autoimmunity, and combined 
immunodeficiency should be screened for ICOS mutations.
Keywords: icOs deficiency, common variable immunodeficiency, hypogammaglobulinemia, autoimmunity, 
immune dysregulation, combined immunodeficiency, opportunistic infections
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Schepp J, Chou J, Skrabl-Baumgartner A, Arkwright PD, Engelhardt KR, 
Hambleton S, Morio T, Rother E, Warnatz K, Geha R, Grimbacher B.  
14 Years after Discovery: Clinical Follow-up on 15 Patients with Inducible Co-
Stimulator Deficiency.  
Frontiers in Immunology 2017, 8. 
 
 
Copyright: 
© 2017 Schepp, Chou, Skrabl-Baumgartner, Arkwright, Engelhardt, Hambleton, Morio, Röther, Warnatz, 
Geha and Grimbacher. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publication in this journal is 
cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms. 
DOI link to article: 
https://doi.org/10.3389/fimmu.2017.00964  
Date deposited:   
10/10/2017 
2Schepp et al. ICOS Deficiency: Clinical Follow-up
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 964
inTrODUcTiOn
Common variable immunodeficiency (CVID) is the most preva-
lent primary immunodeficiency in adults (1) with an estimated 
incidence of 1:25,000–1:50,000 (2). Clinically, patients present 
with an increased susceptibility to infections, autoimmune mani-
festations, and an increased risk of malignancy (3). The disease is 
defined by a marked decrease (at least 2 SD below the mean for 
age) in serum immunoglobulin G (IgG) and IgA and/or IgM, and 
an age of greater than 4 years at diagnosis independent of onset 
(https://esid.org/Working-Parties/Registry/Diagnosis-criteria).
Over the last 14 years, various monogenic defects have been 
identified to be the cause of CVID-like disease (4), allowing for 
more precise diagnosis and comparability within the subgroups of 
this heterogeneous disease. Understanding the molecular mecha-
nisms underlying CVID should lead to more specific treatment. 
The first described monogenic defect causing CVID-like disease 
was the lack of the inducible co-stimulator (ICOS). Following the 
initial description of this monogenic defect in 2003 (5), a number 
of other patients have been identified worldwide. Of the seven 
families, three came from Germany (5, 6), one from Austria (6), 
one from Japan (7), one from Kuwait (8), and one from UK with 
Pakistani background (9).
The ICOS gene has five exons with 2,620 nucleotides, encoding 
a 199-amino acid protein that forms a 55–60 kDa disulfide-linked 
homodimer. ICOS is located very close to the CTLA-4 and CD28 
genes on chromosome 2q33–34 (10). It is exclusively upregulated 
on activated T-cells.
Like CD28, but unlike CTLA4 and programmed cell death 
protein 1, ICOS delivers a positive co-stimulatory signal to the 
T-cell (11). The functions of CD28 and ICOS are only partially 
overlapping. CD28 is constitutively expressed on naïve and 
mature T-cells, while ICOS expression is low on naïve T-cells and 
upregulated upon T-cell receptor stimulation (11). In spite of some 
differences in intracellular-associated molecules, CD28 and ICOS 
share common signaling pathways like phosphorylation of Erk1/2, 
protein kinase B, phosphoinositide-dependent kinase-1, p38 (12), 
and recruitment of phosphatidylinositol-3-kinase (PI3K) (13). 
Signaling through both ICOS and CD28 induces proliferation, 
cell survival, and differentiation. ICOS co-induces the secretion 
of IL-4, IL-5, IL-6, granulocyte-macrophage colony-stimulating 
factor, TNF-α, and interferon gamma (IFN-γ). Moreover, ICOS 
induces IL-10 secretion (14), whereas CD28 induces IL-2 (10). 
ICOS-L is the unique ligand of ICOS. ICOS-L is constitutively 
expressed on both lymphoid and non-lymphoid tissues. 
Inflammatory stimuli, such as TNF-α, IFN-γ, and lipopolysaccha-
ride, lead to its upregulation (15). CD28, however, binds to CD80 
and CD86, which are expressed by antigen presenting cells like 
B-cells, monocytes, macrophages, and immature dendritic cells 
(16). Finally, both CD28 and ICOS are crucial for the development 
and maintenance of regulatory T-cells (Tregs) (17, 18).
A distinct role of ICOS is the generation and maintenance of 
germinal centers (GCs) in lymphatic tissues. ICOS deficiency, 
therefore, results in deficient formation of memory B-cells 
and impaired switched antibody responses (19). ICOS is also 
considered to be a crucial survival signal for C–C chemokine 
receptor type 5 (CXCR5)-positive follicular T-helper-cells (TFH) 
(20). ICOS is highly expressed on those cells, which are primar-
ily localized in the light zone of the GC (21). ICOS signaling is 
crucial for the migration of TFH-cells from the T–B cell border 
into the follicle. This is facilitated by two mechanisms: ICOS-
dependent upregulation of the chemokine receptor CXCR5 (22) 
results in attraction of the T-cells toward the B-cell follicle via the 
chemokine ligand chemokine (C–X–C motif) ligand 13, which is 
secreted by follicular dendritic cells. Moreover, ICOS triggering 
has been shown to promote persistent motility of T-cells in a PI3K-
dependent manner, independent of its co-stimulatory function 
(23). Costimulation via ICOS is thought to be responsible for the 
induction of IL-10 (24) and IL-21 in TFH (25). These cytokines 
are important for the maintenance of GCs and thereby the dif-
ferentiation of B-cells into long-lived switched memory cells and 
plasma cells (26). This explains why ICOS deficiency classically 
manifests with a severely impaired memory B-cell compartment.
The phenotype of ICOS-deficient patients highlights various 
effects of this deficiency on their immune system. This paper 
provides an update on all 15 published patients diagnosed with 
ICOS deficiency to date and available clinical data. We sought to 
compare their clinical and immunological phenotype, and pro-
vide clinical follow-up and therapeutic approaches for treating 
ICOS-deficient patients.
MaTerials anD MeThODs
We describe the clinical and laboratory data of 15 patients with 
ICOS deficiency. Previous case reports as well as direct clinical 
evaluation of the patients by their attending physicians were used 
as source material. Data from one child of family 6, the twin sister 
of patient #12, was not reviewed, as she had died of a septic shock 
in infancy and little is known about her clinical condition. Written 
consent was obtained of all patients or their parents, respectively. 
This study was conducted under the approved ethics protocol No. 
295/13, dated July 17, 2013, from the University clinic, Albert 
Ludwigs University Freiburg.
resUlTs
clinical Manifestations
Clinical features of ICOS deficiency varied significantly, including 
one asymptomatic patient (now aged 15). The average age of onset 
Abbreviations: CVID, common variable immunodeficiency; ICOS, induc-
ible co-stimulator; CTLA-4, cytotoxic T-lymphocyte-associated Protein 4; PD1, 
programmed cell death protein 1; Erk1/2, extracellular signal-regulated kinase 
1/2; PKB, protein kinase B; PDK1, Phosphoinositide-dependent kinase-1; PI3K, 
phosphatidylinositol-3-kinase; IL, interleukin; GM-CSF, granulocyte-macrophage 
colony-stimulating factor; IFN-γ, Interferon gamma; Tregs, regulatory T-cells; 
GC, germinal center; CXCR5, C-C chemokine receptor type 5; TFH, follicular 
T-helper-cells; CXCL13, chemokine (C-X-C motif) ligand 13; FDC, follicular 
dendritic cells; HPV, human papilloma virus; Ig, immunoglobulin; CMV, cyto-
megalovirus; ITP, idiopathic thrombocytopenic purpura; LGL T-cells, T-cell large 
granular lymphocyte cells; SCIG, subcutaneous immunoglobulin; IVIG, intrave-
nous immunoglobulin; IBD, inflammatory bowel disease; HSCT, hematopoietic 
stem cell transplantation; HLA, human leukocyte antigen; TEM, effector memory 
T-cell; TCM, central memory T-cell; FoxP3, Forkhead box P; TGF-β, transforming 
growth factor beta; HHV6, human herpesvirus 6; Btk, Bruton’s tyrosine kinase; 
CID, combined immunodeficiency.
FigUre 1 | Distribution of clinical features in inducible co-stimulator (ICOS) deficiency. Percentages of a specific symptom depict the proportion of symptomatic 
patients within 15 ICOS-deficient patients. Deep blue bars represent hypo-/dysgammaglobulinemia, deep red bars cluster recurring infections, the bright red bar 
highlights opportunistic infections, green bars indicate autoimmunity and immune dysregulation, the orange bar represents malignancies, and the yellow bar 
indicates neurologic/psychiatric features. Immune dysregulation, autoimmune manifestations, inflammatory bowel disease, severe eczema, lymphoproliferation, 
granuloma (according to ESID Registry—Working Definitions for Clinical Diagnosis of PID).
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of symptoms was 14  years, ranging from 1  month to 35  years, 
with six patients only showing first symptoms in adulthood. One 
patient (#1) died at age 44 of malignancy [human papilloma virus 
(HPV)-associated vulvar carcinoma], one patient (#4) died at age 
37 due to complications of an unrelated condition, and one patient 
(#14) died at age 6 years following a capillary leak syndrome on 
day 5 post hematopoietic stem cell transplantation (HSCT). The 
patients’ age at evaluation ranged from 3 to 56 years, with a total 
follow-up time of 122  years (ranging from 1 to 13  years). Six 
patients were female, 10 were male. An overview of the distribu-
tion of the clinical features is given in Figure 1. Supplementary 
text and Table S1 in Supplementary Material provide a detailed 
summary of the individual clinical manifestations and Table S2 
in Supplementary Material laboratory values.
The infectious phenotype of the ICOS-deficient patients 
varied, but mainly consisted of bacterial and Herpes simplex 
or cytomegalovirus (CMV) infections. However, two patients 
also suffered from defective handling of a human herpesvirus 
6 (HHV6) infection or an opportunistic Pneumocystis jirovecii 
infection, respectively.
Seventy-three percent (11/15) had recurrent infections. 
Respiratory infections were the predominant problem with 60% 
(9/15) of patients suffering from upper respiratory infections and 
lower respiratory infections including pneumonia. Lobectomy 
was performed in one patient (#7) following necrotizing pneu-
monia, and three patients suffered from chronic parenchymal 
lung damage such as bronchiectasis (#3, #7) and emphysema (#5).
Eight patients had recurrent Herpes virus infections including 
four cases of Herpes simplex (patient #2, #5, #6, and #7), four 
cases of CMV infection (patient #7, #9, #10, and #12), and one 
case of HHV6 (#14). The severity of these viral infections varied: 
two patients (#5 and #6) had moderate to severe recurring herpes 
labialis that could be controlled by topical treatment. Patient #2 
had recurring herpes keratitis and developed an ulcer leading to 
keratoplasty at age 39 years, requiring treatment with oral pred-
nisolone and valacyclovir. Patient #7 suffered of genital herpes 
at age 24 with strong local symptoms but no signs of systemic 
infection as in fever or elevated CRP levels. She was successfully 
treated with intravenous acyclovir. A mild relapse 1  year later 
was treated with oral valacyclovir. Patient #7 was diagnosed with 
CMV at age 28 in the context of an aggravation of her inflam-
matory bowel disease (IBD)-like symptoms. After oral valgan-
ciclovir treatment, CMV-specific PCR turned negative. Several 
reactivations detected by PCR positivity in blood, urine, and 
stools did not correlate with an exacerbation of symptoms and 
were consequently not treated. Her brother’s (patient #9) CMV 
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infection first manifested with severe bloody diarrhea, fever, and 
hepatopathy at age 14. He required 7 days of intravenous aciclovir 
followed by 14 days of oral valganciclovir. Two reactivations were 
treated successfully with 14 and 21 days of valganciclovir. Patient 
#10 had recurrent CMV vulvovaginitis at age 45 requiring long-
term oral valganciclovir. At age 48, she developed abdominal 
pain associated with bloody stools, and was diagnosed with CMV 
colitis by biopsy and by PCR on blood and the biopsy specimen. 
After 3 weeks of ganciclovir, all symptoms resolved. During an 
episode of Candida-induced acute respiratory failure and severe 
chronic diarrhea at age 1 month, patient #12 was also noted to 
have low-level CMV viremia. Posttransplant, he developed a 
CMV reactivation treated successfully with ganciclovir and 
CMV-specific immunoglobulin (Cytogam). One patient (#14) 
showed defective handling of HHV6 colitis. The virus was 
confirmed in samples from the sigmoid, duodenum, and liver. 
Following treatment with intravenous ganciclovir and then oral 
valganciclovir together with nitazoxanide, liver, and duodenal 
samples became negative for HHV6. However, a sigmoid biopsy 
remained positive and clinically, severe colitis associated with 
diarrhea and abdominal pain persisted.
Three patients suffered from other intestinal infections: 
Campylobacter enteritis in #2, Salmonella enteritis in #4, and 
norovirus, adenovirus, and Cryptosporidium enteritis in #14. 
Other infections included otitis media (#3), Staphylococcus impe-
tigo (#1), severe verrucosis (#6), vaginal ulcer (#10), Helicobacter 
cinaedi bacteremia (#10), Escherichia coli sepsis (#10), and 
lymphocytic meningoencephalitis of unclear cause (#5). An 
opportunistic infection was observed in one patient (#12), who 
suffered from Pneumocystis jirovecii pneumonia at age two.
Autoimmunity and immune dysregulation were observed in 
73% (11/15) of patients. Nine patients were affected by enteropa-
thy, three by arthritis and one patient by interstitial pneumonitis 
(#10). Four patients developed splenomegaly (one accompanied 
by mild thrombocytopenia), and three hepatomegaly. Non-
infectious hepatitis occurred in three patients: patient #1 had 
an alcoholic steatohepatitis. In patient #4, the pathogenesis of 
hepatitis remained unclear. Drug-induced toxicity was suspected 
according to histological findings and intake of a quinolone 
antibiotic shortly before. No serologic evidence of autoimmune 
hepatitis was found, and sarcoidosis was excluded histologically. 
In patient #15, a flare of hepatitis resolved spontaneously and 
a specific cause was not found either. Two each had thrombo-
cytopenia and neutropenia, respectively. Four patients suffered 
from psoriasis and two patients had eczema. Two patients had 
granulomas: in one patient with chronic eczema, a biopsy showed 
a granulomatous inflammatory process with sarcoid-like lesions. 
In patient #1, multiple small non-caseating granulomas were 
found in one of two lymph nodes examined following lymphad-
enectomy after recurrence of her vulval carcinoma.
Two patients developed cancer: patient #1 developed a verru-
cous squamous epidermal carcinoma of the vulva associated with 
human papilloma virus infection at age 34 from which she died 
aged 44. In patient #6, large granular lymphocyte T-cells with 
clonal expansion were confirmed at age 51. In the same patient, 
a pre-auricular squamous cell carcinoma grade I was excised at 
age 53.
impaired immune Function in  
icOs-Deficient Patients
Inducible co-stimulator deficiency can affect the T-cell and 
the B-cell compartments. All patients had low TFH and low 
switched memory B-cells. Other abnormalities were not present 
in all patients, indicating phenotypic variability (see Table S2 in 
Supplementary Material).
T-Cell Phenotype
Although all patients presented with normal absolute peripheral 
T-cell counts, and immunophenotypic analysis was not uniform, 
the following T-cell subset abnormalities were observed: In 
families 1–4, 6, and 7, there was a normal distribution of naïve, 
memory, and effector T-cells, except for patients #2, #6, and #7 
who had inverted CD4+/CD8+ ratios (19), and patient #12 from 
family 6 who had high CD8+ effector memory T-cells (TEMs). 
In family 5, however, there was a severe reduction in memory 
T-cell numbers. In these patients, further analysis of the memory 
subsets showed that CCR7+ CD62L+ CD45RO+ central memory 
T-cells as well as CCR7−CD62L−CD45RO+ TEMs were signifi-
cantly reduced in both CD4+ as well as CD8+ T-cells (7).
In all families, a severe reduction of circulating TFH, defined 
as CXCR5+CD45RO+ memory CD4+ T-cells, was found, despite 
normal memory T-cell counts. This finding is in concordance 
with the fact that ICOS deficiency is associated with an impaired 
upregulation of CXCR5 on T-cells after stimulation (8, 9, 20).
FoxP3+ regulatory T cell counts were normal in the patients 
from families 1-4, family 5, and family 6 (7, 8). In contrast to 
the others, in family 5, there was a reduction of regulatory T cell 
FOXP3 expression as measured by mean fluorescence intensity, 
and a decrease in the CD45RO+CTLA4+ subset producing 
IL10, although, transforming growth factor beta-producing 
CD45RA+CTLA4dull+ cells were unaffected. The intensity of 
CTLA4 expression on the CTLA4+ subset was also diminished 
in those patients (7). These markers were not determined in the 
other families.
Patient #6 from family 3 developed an expansion of T-cell 
large granular lymphocyte cells with clonal restriction suspi-
cious of lymphoma. He recently presented with a distinct 
expansion of double negative T-cells and CD8+ effector T-cells 
with elevated activation markers (HLA-DR), alongside a severe 
decrease of CD4+ T-cells, CD8+ T-cells, NK-cells, and ongoing 
B-cell lymphopenia. Within the CD8+ T-cell compartment, the 
naïve T-cells were severely decreased. For details on the patient’s 
clinical course, please see his case report in the Supplementary 
material.
B-Cell Phenotype
B-cell counts were decreased in all adult patients, whereas the 
children from family 4, 6, and 7 presented with normal B-cell 
counts upon diagnosis (8, 9, 19). However, when reanalyzed 
12 years later after diagnosis, patients from family 4 also showed 
decreased B-cell counts. Two stages of B-cell development were 
disturbed in ICOS-deficient patients. In five of six adult patients 
in families 1–3, a severe reduction in absolute numbers of circu-
lating naïve CD27− B-cells was observed (19). Consecutive bone 
TaBle 1 | Immunoglobulin levels in [g/L] of inducible co-stimulator -deficient 
patients at the time of diagnosis [immunoglobulin G (IgG)] and after initiation of 
immunoglobulin substitution therapy (IgG, IgA, IgM).
Patients (age at 
measurement in 
years)
igg on 
intravenous 
immunoglobulin 
(iVig)/
subcutaneous 
immunoglobulin
igg without 
iVig
iga igM
Fam1—01 (44) 5.2 1.9 <0.25 <0.17
Fam1—02 (46) 6.2 2.9 0.27 <0.16
Fam2—03 (47) 2.4 1.1 0.14 0.1
Fam2—04 (37) 2.3 <1.4 0.05 0.55
Fam3—05 (56) 8.51 3.2 <0.06 0.29
Fam3—06 (52) 7.21 N/A <0.07 0.97
Fam4—07 (28) 13.6 2.85 <0.06 <0.17
Fam4—08 (15) 3.54 1.54 0.6 0.27
Fam4—09 (15) 3.88 0.48 0.11 <0.17
Fam5—10 (47) 7.97 3.15 0.14 0.61
Fam5—11 (44) 6.5 6.11 0.1 4.32
Fam6—12 (2) 1.5 1.1 <0.007 0.84
Fam6—13 (10) N/Aa 6.5 N/A N/A
Fam7—14 (5) 6.32 2.07 0.43 0.17
Fam7—15 (4) N/Aa 1.5 0.29 0.32
Normal range (2)b 4.24–10.51 4.24–10.51 0.14–1.23 0.48–1.68
Normal range (4–5)b 4.63–12.36 4.63–12.36 0.25–1.54 0.43–1.96
Normal range (9–10)b 6.08–15.72 6.08–15.72 0.45–2.36 0.52–2.42
Normal range (adults)b 6.39–13.49 6.39–13.49 0.7–3.12 0.56–3.52
N/A, not available.
aPatient did not receive immunoglobulin substitution.
bReference values according to Jolliff et al. (27).
Underlined and italic numbers mean reduced or increased values, respectively.
FigUre 2 | Treatment of inducible co-stimulator (ICOS) deficiency. Total 
number of patients: 15. The deep blue bar indicates immunoglobulin 
substitution, green bars show antibiotics and anti-virals, deep red bars 
represent immune modulatory drugs, and the bright red bar highlights 
hematopoietic stem cell transplantation (HSCT).
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marrow biopsies of patients #3, #4 (19), and later on also in patient 
#5 showed a relative expansion of the cytoplasmic Ig-negative 
pre-B-I cells indicating a partial block of differentiation into the 
cytoplasmic Ig-positive pre-B-II cell stage. In contrast to previous 
reports (19), absolute numbers of naïve B-cells were now also 
decreased in the patients of family 4, and in patient #5, who now 
presented with low absolute B-cell counts as well as decreased 
naïve B-cell counts. They were also low in patient #10 from fam-
ily 5, whereas her brother (patient #11) showed almost normal 
numbers of naïve B-cells at age 44, in spite of low total B-cell 
counts. In families 6 and 7, the children’s (aged from 3 to 11 years) 
normal total B-cell counts went along with high naïve B-cell 
numbers. Further B-cell development in ICOS-deficient patients 
seems unimpaired until the differentiation into class switched 
memory B-cells: CD19+CD27+IgD− switched memory B-cells 
were markedly decreased at varying levels (but still detectable in 
14/15 patients) in all ICOS-deficient patients (7–9, 19). Somatic 
hypermutation in the V region of the IgM gene was normal in 
three patients (19).
Immunoglobulins and Cytokines
In keeping with low class switched B-cells, hypogammaglobuline-
mia was observed in all but one patient (#13). Immunoglobulin 
levels are indicated in Table 1. IgG levels were consistently low 
in all patients but #13, who had low IgG levels at age 3 years but 
low normal values when re-evaluated at age 10. In ten patients, 
IgG levels were <3  g/L at diagnosis. 82% (12/15) had also 
low IgA levels, whereas IgM levels varied. 60% (9/15) had 
decreased IgM levels, five patients had normal, and one patient 
(#11) had elevated IgM levels. Specific antibody responses to 
vaccinations were not detectable, except for low levels of a phage-
specific IgM in patient #1, a low titer of anti-diphtheria antibodies 
in patient #8, protective tetanus titers in patient #13, and measles 
and mumps IgG in patient #15. (Vaccination levels of patient 
#13 were not measured before immunoglobulin substitution was 
started). Anti-Borrelia burgdorferi IgM were detected once in the 
cerebrospinal fluid of patient #5.
Production of various cytokines was impaired in ICOS-
deficient patients. In family 5, IL-10, IL-17, IL-4, IL-5, as well as 
TNFα, TNFβ and IFN-γ were decreased (7). In families 1 and 2, 
IL-10 and IL-17 secretion were also notably impaired, whereas 
IFN-γ and IL-13 secretion were normal (19).
Treatment
Figure 2 gives an overview on the drugs used for the treatment 
of ICOS-deficient patients. Eighty percent (12/15) of the patients 
received immunoglobulin substitution therapy. Eight patients 
were treated with subcutaneous immunoglobulins, one only 
during the winter months. Four were treated with intravenous 
immunoglobulins, not including patient #13 who had low nor-
mal IgG trough levels. Two additional patients did not receive 
immunoglobulins; #11 did not have recurrent infections and the 
parents of #15 refused treatment.
Despite immunoglobulin replacement, 33% (5/15) needed 
antibiotics. Of those, two patients (#1, #7) received regular 
antibiotic prophylaxis with norfloxacin and clarithromycin, 
respectively. Four patients received antiviral drugs. Two patients 
were treated with valganciclovir for a CMV infection. The HHV6 
infection in patient #14 was treated with intravenous ganciclovir 
followed by oral valganciclovir together with nitazoxanide. 
Valaciclovir was used in patient #2 for Herpes keratitis.
Corticosteroids were prescribed to 40% (6/15) of patients. 
Five patients received systemic corticosteroids for the following 
FigUre 3 | Specific clinical manifestations of inducible co-stimulator (ICOS) deficiency. (a) Chest X-ray of patient #12 at the time of respiratory failure shows 
multifocal patchy consolidative opacities with moderate pulmonary edema. (B) Colonoscopy of patient #9 shows inflammatory bowel disease. (c) Finger of patient 
#7 with psoriasis of the nail and secondary Candida infection. (D) Hand X-ray of patient #10 shows erosive changes suspicious of rheumatoid arthritis.
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indications: immune thrombocytopenia and neutropenia, IBD, 
symmetric rheumatoid arthritis, and herpes keratitis. One 
patient received intra-articular steroids to treat his ankle joint 
arthritis. Enteral budesonide was used in one patient with IBD. 
Additional steroid-sparing agents were necessary in two patients: 
#6 received cyclosporine for T-cell mediated neutropenia, and 
#10 received methotrexate for rheumatoid arthritis (Figure 3). 
Two patients with IBD (Figure 3) improved with mesalazine. In 
patient #7, antihistamines, antipsoriatic, and antimycotic drugs 
were applied as topical treatment of her psoriatic nail disease 
(Figure 3).
Three ICOS-deficient patients have undergone HSCT. One 
patient (#12) received a matched, related donor transplant at 
age 2 following a severe Pneumocystis jirovecii infection leading 
to respiratory failure (Figure 3). His symptoms have improved 
significantly and he is doing well 2  years posttransplant. One 
patient (#15) suffered from severe colitis and received an 
unrelated 11/12 human leukocyte antigen matched transplant 
following reduced intensity conditioning at age 6. However, she 
developed a capillary leak syndrome on day 5 posttransplant with 
respiratory distress followed by toxic epidermal necrolysis, and 
died. The last patient (#6) was transplanted seven months ago 
at age 53 for persistent agranulocytosis. After reduced intensity 
conditioning, he received a matched unrelated donor transplant. 
On day 30, complete donor chimerism was confirmed alongside 
a complete engraftment. 233 days posttransplantation he showed 
no additional major complications and no signs of GvHD.
genetics
Figure 4 gives an overview on the seven families’ pedigrees. The 
inheritance was strictly autosomal-recessive in all families, and 
all mutations led to a failure to detect the protein on the surface 
of activated T-cells. Families 1–4 had a homozygous deletion of 
a 1,815 base pair region including exon 2, intron 2, exon 3, and 
parts of intron 3 of the ICOS gene (c.126-568.del) (5, 6). This out 
of frame deletion led to a premature stop codon and shortened 
transcript (5). A common ancestor is assumed for these four 
families. In the unrelated family 5, sequencing of the ICOS gene 
revealed a homozygous deletion of a T at codon 285, leading 
to a frameshift and the introduction of a stop codon at amino 
acid position 121 and resulting in a truncated ICOS transcript 
(c.285delT) (7). The patients from family 6 from Kuwait were 
found to carry a single nucleotide homozygous deletion in Exon 
2 (c.90delG), leading to a frameshift and premature stop codon 
in Exon 2 (8). In the children of the consanguineous family 7, 
a homozygous 10 base-pair deletion in ICOS (c.321_330del) led 
to a frameshift and a premature stop after 10 codons in the new 
reading frame (p.F108YfsX118) (9).
FigUre 4 | Pedigrees of inducible co-stimulator (ICOS)-deficient families. Twins are joined by diagonal lines. Healthy siblings of family 7 are depicted as gender-
neutral rhomb symbols to protect the family’s privacy. Specific ICOS mutations and patient numbers are depicted underneath the affected homozygous family 
members. The genotype of the deceased male twins in family 3 as well as of the healthy male sibling in family 4 is unknown (indicated by a question mark 
underneath the symbols).
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DiscUssiOn
These 15 ICOS-deficient patients teach various lessons about 
the role of ICOS: All reported ICOS mutations were deletions, 
resulting in an undetectable ICOS protein. Despite this uniform 
effect on protein expression, the clinical presentations varied. The 
onset of disease was very variable in the cohort. As patient #8 
still did not display any symptoms at age 15 in contrast to her 
dizygotic twin brother, her condition will be watched closely. In 
case she develops symptoms, this might give new insights into 
triggering events.
Inducible co-stimulator deficiency clearly has its major 
impact on the maintenance of GCs and, therefore, on the 
normal development of class switched B-cell responses. This 
resulted in hypogammaglobulinemia in all but one patient, 
leading to increased susceptibility to bacterial infections 
in most individuals. In some patients with ICOS deficiency, 
the pattern of viral susceptibility rather suggests a combined 
immunodeficiency (CID). There were recurrent Herpes 
infections in families 1, 3, and 4 (5, 19), and prolonged viral 
infections in childhood in family 5 (7). This is also relevant 
for the potential role of ICOS in tumor surveillance for virally 
induced tumors, highlighted by the HPV-associated vulvar 
carcinoma in patient #1 and the squamous cell carcinoma in 
patient #6. The latter is supported by data demonstrating that 
ICOS stimulation enhances NK-mediated tumor cell killing 
in mice (28). Also, impaired T-cell activation was reported in 
ICOS knockout mice (29).
Intriguingly, in the recently reported families 6 and 7, the 
occurrence of Pneumocystis jirovecii pneumonia, defective 
handling of HHV6 and possibly also of Cryptosporidium, were 
associated with a very early onset of disease (8, 9). None of 
the other ICOS-deficient patients had frankly opportunistic 
infections or showed signs of a severe T-cell deficiency. Even 
in the patients from family 5 who showed deviations in the 
T-cell memory compartment, no opportunistic infections were 
observed. It remains to be clarified whether this is a variation 
of the clinical presentation of ICOS deficiency or if additional 
modifiers are involved.
Additionally to the infectious profile, the increased prevalence 
of immune dysregulation (77%) also suggests an underlying CID. 
This is highlighted by the patients’ susceptibility to psoriasis (4/15 
patients) and enteropathy (9/15 patients). Immune dysregula-
tion in ICOS deficiency seems less pronounced than in LRBA 
deficiency [in which 95% of patients are affected (30)]. The 
prevalence of immune dysregulation in CVID seems to depend 
on the cohort. Gathmann et al. found 29% of the patients suffer-
ing from autoimmunity and 9% from enteropathy (2), whereas 
Cunningham-Rundles and Bodian found 22% of autoimmunity 
and 6% of IBD (3). Several observations hint toward a role of 
ICOS-mediated signaling in autoimmunity. For example, it 
has been shown that plasmacytoid dendritic cells prime IL-10-
producing T  regulatory cells via ICOS-L (31). Yet, the precise 
autoimmune context of ICOS triggering on T-cells and the 
consecutive T-cell help to the antigen presenting bystander cells 
has not yet been defined.
Several abnormalities of the B- and the T-cell compartment 
should be highlighted: In ICOS deficiency, there seems to 
be a progressive loss of B-cells, reflected by a normal B-cell 
count in childhood but impaired counts in all but two adult 
patients, including those followed longitudinally. In several 
ICOS-deficient patients, a block in B-cell development after 
the pre-BI stage was reported. This developmental block is 
not ICOS-specific, as it was also detected in ICOS-positive 
CVID-like patients (32), and it is reminiscent of the severe 
block seen in Bruton’s tyrosine kinase-deficiency (33). Also, 
naïve B-cell counts were reduced in most, but not all ICOS-
deficient patients. This might hint toward a progressive bone 
marrow output failure. Switched memory B-cells are reduced, 
but still detectable at varying levels in all ICOS-deficient 
patients. Their severe reduction is in part explained by the 
crucial role of ICOS:ICOS-L interactions in the GC; however, 
B-cell differentiation seemingly does not totally depend on 
this support.
Regarding the T-cell compartment, the decreased proportion 
of memory T-cells that were found in several ICOS-deficient 
individuals could be a specific finding of this condition: ICOS 
was shown to control the pool size of TEMs (34). Nevertheless, 
this phenomenon was not present in the entire cohort, and 
the CD8 effector memory cells were even high in one patient 
(patient #12), again possibly due to chronic infection by 
Candida, CMV and Pneumocystis jirovecii. In contrast, the 
reduction of circulating CXCR5+CD45RO+ CD4 TFH-cells 
was reported in all ICOS-deficient patients and coincides with 
an impaired GC formation in lymphoid tissues as it has been 
observed also in CD40L deficiency (35). This accords with a 
role for ICOS as a crucial survival signal for CXCR5+ TFH-
cells (20). ICOShigh T-cells have been shown to produce IL-10 
(36), and maintain the pool size of FOXP3+ Tregs (34). These 
suggestions from the mouse model could only be affirmed in 
the patients of family 5, who showed a reduction of FOXP3 
expression together with contraction of the CD45RO+CTLA4+ 
Treg subset producing IL10. However, these findings were not 
confirmed in any of the other ICOS patients who were evalu-
ated for FOXP3 expression, suggesting a less stringent need for 
human ICOS expression in the development or maintenance of 
these cell types.
The patients’ interleukin-profile also varied substantially in 
between the reported patients, but, it is striking that in all patients 
who were assessed for cytokine expression profiles, IL-17 was 
markedly decreased. Pathogenic mutations of several genes can 
impair TH17 development, including STAT1, STAT3, DOCK8, 
AIRE, and IL-17RA, or IL-17F (37). Most of the associated condi-
tions confer a risk of (invasive) Candida infections, as was also 
observed in patient #12, who suffered from Candida-induced 
acute respiratory failure at 1 month of age. Otherwise, there were 
only occasional local super-infections in patients with psoriasis 
(e.g., patient #7, Figure 3). P. jirovecii pneumonia (patient #12), 
CMV infections (patients #7, #9, #10, and #12) and S. aureus skin 
infections (patient #1) have been associated with impaired TH17 
development. In the two siblings of family 5, the production 
of IL-22 was tested additionally and found to be normal. IL-22 
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is another Th17 cytokine that is crucial in the pathogenesis of 
psoriasis and both patients had psoriasis (as well as patient #7 
and #9 from family 4). While it remains unclear whether IL-17A 
and IL-22 are produced by the same Th17 subset (38, 39), these 
data suggest that an IL-22-producing subset is not impaired in 
ICOS deficiency.
The spectrum of clinical manifestations led to a broad spec-
trum of treatments. Almost all ICOS-deficient patients were on 
immunoglobulin replacement therapy. Corticosteroids were also 
used frequently, and two patients needed additional steroid- 
sparing agents. Most ICOS-deficient patients could be managed 
with conservative therapy. This is especially true for patients with 
a late onset of disease and the main sequelae being hypogam-
maglobulinemia. However, three ICOS-deficient patients 
received HSCT due to CID (#12), persistent agranulocytosis (#6) 
or severe colitis (#15); the latter died following posttransplant 
complications. Early transplantation before accumulation of 
disease complications and acquisition of viral infections may 
improve outcome in a subset of patients with significant T-cell 
dysfunction, autoimmunity, life-threatening infections or severe 
cytopenias.
The clinical and laboratory data from these 15 ICOS-
deficient patients, indicate that more emphasis should be 
placed on the T-cell dysregulation in this disorder. In 2013, 
ICOS deficiency was classified as “Predominantly antibody 
deficiency“ by the International Union of Immunological 
Societies Expert Committee on Primary Immunodeficiency 
(40), but in 2015, it was reclassified as CID (41), describing 
the clinical phenotype with the key words “autoimmunity, 
gastroenteritis, may have granuloma.” This classification is 
certainly supported by our data. In addition, the rare occur-
rence of opportunistic infections should be considered as pos-
sible alteration of the phenotype. CD40L deficiency is another 
disease that was first described as a defect of B-cell isotype 
switching but is now known to be a defect of co-stimulatory 
T-cell help and function (40). As with CD40L deficiency, ICOS 
deficiency should be considered in CVID-like disease as well 
as in CID patients.
cOnclUsiOn
Inducible co-stimulator deficiency has a broad clinical and 
immunological phenotype. Whereas in the initially pub-
lished families, ICOS deficiency seemed to produce isolated 
hypogammaglobulinemia, the recently published patients 
showed more complex phenotypes with prominent autoim-
mune features and opportunistic infection profiles. There 
is now ample evidence that B-cell counts decline during the 
course of the disease, possibly related to a progressive bone 
marrow output failure. Genetic analysis is required to reli-
ably distinguish ICOS deficiency from other immunological 
defects. ICOS deficiency should be ruled out in patients in 
whom immunodeficiency and autoimmunity or immune 
dysregulation coincide.
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